This is an advanced reference and clinical text documenting the latest advances and current knowledge on all aspects of diagnosing and treating renal, bladder and prostate cancer. It contains 33 original, new chapters by high-level experts in urology, oncology, endocrinology, immunohematology, and pathology from leading medical centers in the United States and Europe. Their contributions provide essential updates on today's most intensely researched and debated issues in renal, bladder and prostate cancer. These include molecular genetics, organ-sparing surgery, tumor nephrectomy, metastatic renal cell carcinoma, gene therapy, optimal strategies for early detection, accuracy of grading, avoiding aggressive treatment when unneeded, advances in radiotherapy, minimal invasive treatment alternatives, endocrine treatment, androgen monotherapy, quality of life issues, new approaches to drug development, intravesical chemotherapy, adjuvant therapy, urinary cytokines as predictors, bladder preservation, orthotopic urinary diversion, systemic treatment, and contemporary approaches for chemotherapy. Massively referenced and fully indexed.
Molecular genetics of renal cell carcinoma. Limits of cure by surgery in renal cell carcinoma. Organ-sparing surgery: magic bullet or tragic insanity? Transabdominal or retroperitoneal approach for tumor nephrectomy: an easy choice? Surgery for metastatic renal cell carcinoma: a matter of attitude? Interferons in metastatic renal cell carcinoma: a tradition to be maintained? Interleukin-2 in renal cell carcinoma. Gene therapeutic approaches for renal cell carcinoma: has the future arrived? Cytotoxic T lymphocyte priming versus tolerance induction. Prostate cancer in Japan: what are the differences? Decreasing prostate cancer mortality in the USA. Is the value of screening already proven? Update on the European Randomized Study of Screening for Prostate Cancer: light at the end of the tunnel. What is the optimal strategy for early detection of prostate cancer? How many biopsies should be taken for proper diagnosis and grading? Accuracy of grading: can it be replaced by other prognostic tissue factors? Present and future. Is cure of prostate cancer possible in those for whom it is necessary? Can aggressive treatment be avoided in those who may not need it? Advances in radiotherapy of localized prostate cancer: improved effectiveness? Minimal invasive treatment alternatives for localized prostate cancer using thermal therapy or cryosurgery. Endocrine treatment of prostate cancer: the future after maximum androgen blockade and the role of PSA monitoring. Antiandrogen monotherapy. Quality of life in prostate cancer: preliminary results of two studies in patients with extensive disease. Intermittent endocrine therapy for prostate cancer. New approaches to drug development in prostate cancer. Can intravesical chemotherapy prevent progression of superficial bladder cancer? Is intravesical BCG superior to chemotherapy? How long should adjuvant BCG be given? Urinary cytokines after intravesical immunotherapy: are they predictors? Is bladder preservation possible in transitional carcinoma T1G3? Orthotopic urinary diversion in transitional cell carcinoma: are there limits? The place for systemic treatment in invasive bladder carcinoma. Gene therapy in metastatic transitional cell carcinoma of the bladder. Contemporary approaches for chemotherapy of metastatic urothelial cancer. Index.
「Nielsen BookData」 より